Literature DB >> 18635702

Problems associated with long-term treatment with selective serotonin reuptake inhibitors.

C Moret1, M Isaac, M Briley.   

Abstract

Although the selective serotonin reuptake inhibitors (SSRIs), which are now widely used as a first-line treatment for depression and many other psychiatric conditions, are generally well tolerated, they are not devoid of side effects. Most short-term treatment-related side effects of SSRIs are transient and disappear after a few days or weeks. However, following long-term treatment with the SSRIs, some serious adverse events may occur. Some of them can be difficult to recognise because they can resemble residual symptoms of depression. The most serious can be life threatening. They all have a negative influence on the patient's quality of life and are frequently a prime reason for a lack of long-term compliance with the associated increased risk of recurrence of a depressive episode. This article is an overview of the more common adverse events, which are seen with non-acute treatment with the SSRIs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635702     DOI: 10.1177/0269881108093582

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  26 in total

1.  A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients.

Authors:  Haeseong Park; Gwendolyn L Parker; Cecelia H Boardman; Monica M Morris; Thomas J Smith
Journal:  Support Care Cancer       Date:  2011-01-27       Impact factor: 3.603

2.  Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods.

Authors:  Christina L Boisseau; Steven A Rasmussen
Journal:  Contemp Clin Trials       Date:  2018-01-03       Impact factor: 2.226

3.  Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review.

Authors:  Elena Dragioti; Marco Solmi; Angela Favaro; Paolo Fusar-Poli; Paola Dazzan; Trevor Thompson; Brendon Stubbs; Joseph Firth; Michele Fornaro; Dimitrios Tsartsalis; Andre F Carvalho; Eduard Vieta; Philip McGuire; Allan H Young; Jae Il Shin; Christoph U Correll; Evangelos Evangelou
Journal:  JAMA Psychiatry       Date:  2019-12-01       Impact factor: 21.596

4.  ISPMD consensus on the management of premenstrual disorders.

Authors:  Tracy Nevatte; Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen W Freeman; Uriel Halbreich; Khalid Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; David Rubinow; Peter Schmidt; Meir Steiner; John Studd; Inger Sundström-Poromaa; Kimberly Yonkers
Journal:  Arch Womens Ment Health       Date:  2013-04-27       Impact factor: 3.633

Review 5.  Vilazodone: in major depressive disorder.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

Review 6.  Vilazodone: a review in major depressive disorder in adults.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 7.  [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].

Authors:  H Javelot; P-M Llorca; D Drapier; E Fakra; C Hingray; G Meyer; S Dizet; A Egron; C Straczek; M Roser; M Masson; R Gaillard; P Fossati; E Haffen
Journal:  Encephale       Date:  2020-05-04       Impact factor: 1.291

8.  Milnacipran: a unique antidepressant?

Authors:  Siegfried Kasper; Gerald Pail
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

9.  Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good.

Authors:  Paul W Andrews; J Anderson Thomson; Ananda Amstadter; Michael C Neale
Journal:  Front Psychol       Date:  2012-04-24

10.  Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk?

Authors:  Xiaoqin Liu; Natalie C Momen; Nina Molenaar; Anna-Sophie Rommel; Veerle Bergink; Trine Munk-Olsen
Journal:  J Affect Disord       Date:  2021-05-07       Impact factor: 6.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.